Compounded Tirzepatide: Dosage, Cost, Safety, and Where to Get It Online

Compounded tirzepatide is a prescription medicine made for one patient after a licensed provider writes a prescription. It contains tirzepatide, the same active ingredient found in the brand-name drugs Zepbound and Mounjaro.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. In plain terms, it copies two gut hormones that lower appetite and slow how fast the stomach empties, which is why it is used for weight management and type 2 diabetes.

People often search for the compounded version because it has cost far less than the brand-name pens. The important catch: compounded drugs are not FDA-approved. The FDA does not review them for safety, strength, or purity the way it reviews Zepbound and Mounjaro.

It is the same active ingredient, but it is not the same product. Zepbound (for weight management and obstructive sleep apnea) and Mounjaro (for type 2 diabetes) are both made by Eli Lilly, FDA-approved, and tested for purity, strength, and sterility.

Compounded tirzepatide skips that FDA review. It is usually shipped as a multi-dose vial that you draw into a syringe yourself, instead of a single-dose pen. Some compounded versions have used different salt forms or added ingredients that are not in the Lilly product.

Prescribers usually talk about tirzepatide with a "start low, go slow" schedule. The brand label starts at 2.5 mg once a week. That first step is a tolerance dose, not a treatment dose; its job is to help your stomach adjust before the dose increases.

After 4 weeks, the dose typically moves to 5 mg once weekly. From there it can go up by 2.5 mg no faster than every 4 weeks, up to a maximum of 15 mg once weekly. The main maintenance doses studied are 5 mg, 10 mg, and 15 mg.

Brand pens are pre-measured, so you never think in "units." Compounded tirzepatide is different: it comes in a vial, and you draw the dose into a U-100 insulin syringe, where the marks are in units. That is why people ask how many units equal their dose.

Units are not fixed. The number of units depends on two things: how strong the vial is (its concentration in mg/mL) and how much you were prescribed (your dose in mg). The same 5 mg dose can be a different number of units in two different vials.

The conversion depends on vial concentration: dose ÷ concentration gives milliliters, then milliliters × 100 gives U-100 syringe units. Getting this wrong is a real risk with multi-dose vials, so always confirm your vial's concentration with your pharmacy.

Compounded tirzepatide is almost always self-pay — insurance and manufacturer savings cards do not apply. In 2026 most telehealth prices land in the low-to-mid hundreds per month, while brand-name retail runs about five to eight times higher without a program.

The cheapest listing is not automatically the safest route. With compounded tirzepatide, first verify that the prescription and pharmacy path are legitimate.

Compounded tirzepatide is only obtained legitimately through a licensed provider who writes a prescription that a state-licensed 503A pharmacy fills for you as an individual. Some telehealth platforms handle the visit and the pharmacy in one place.

Because of the 2026 rules below, the provider should document a real patient-specific reason. It should not feel like a no-questions checkout for an off-the-shelf compounded product. Use these checks before you order:

Short answer: mostly no, with a narrow exception. Compounded tirzepatide is not "banned" by name, but the legal shield that made it widely available is gone.

Compounding copies of an FDA-approved drug is only allowed during a shortage. The FDA declared the tirzepatide shortage resolved in October 2024. Enforcement discretion then ended for state-licensed (503A) pharmacies on February 18, 2025 and for larger outsourcing (503B) facilities on March 19, 2025. A court upheld the FDA in May 2025 (the case is on appeal).

It went further in 2026. On April 30, 2026, the FDA proposed leaving semaglutide, tirzepatide, and liraglutide off the 503B bulks list entirely, saying there is no clinical need for large-scale compounding. A public comment period ran through June 29, 2026. The FDA also sent warning letters to telehealth companies in early 2026.

Safety depends less on the molecule and more on who made the vial, how it was tested, and how it was handled. Tirzepatide itself has strong clinical trial data behind the brand versions, but a compounded product is not FDA-reviewed.

The FDA has pointed to real problems with compounded GLP-1s: dosing errors from patients measuring their own doses out of multi-dose vials (some serious enough to require hospital care), counterfeit or mislabeled products sold online, and products that arrived warm or were stored incorrectly. As of early 2025 the FDA had logged more than 320 adverse-event reports tied to compounded tirzepatide.

Side effects come from the tirzepatide itself, so they mirror what is reported for Zepbound and Mounjaro. The most common ones are stomach-related and tend to be worst right after a dose increase.

With a compounded multi-dose vial, a drawing or measuring mistake can also cause an accidental overdose, which usually shows up as severe nausea and vomiting. If you have severe belly pain, signs of an allergic reaction, or symptoms that worry you, contact a clinician right away.

For brand-name tirzepatide, Eli Lilly's label allows single-dose pens and vials to sit at room temperature (up to 86°F / 30°C) for up to 21 days, and multi-dose KwikPens for up to 30 days. Once it is out of the fridge, do not put it back, and discard it after that window.

Compounded vials are different. Their room-temperature limit depends on the formula and preservatives, so the 21-day pen rule may not apply. Always follow the storage instructions and beyond-use date printed by your compounding pharmacy.

Brand tirzepatide keeps until its printed expiration date when stored at 36–46°F (2–8°C). Compounded vials carry a shorter beyond-use date set by the pharmacy — often weeks rather than months — because they are made fresh and are not mass-produced.

Zepbound is the FDA-approved brand for weight management and obstructive sleep apnea, sold in pre-measured pens and vials with verified strength and purity. Compounded tirzepatide uses the same active drug and can cost less, but it does not get FDA review and has a much narrower legal path in 2026.

Mounjaro is the FDA-approved brand for type 2 diabetes; some clinicians also prescribe it off-label for weight loss. It uses the same tirzepatide molecule as compounded versions, but with FDA oversight, single-dose delivery, and a clear legal status.